DDInter1276 DDInter899
Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Nelfinavir {u} (Compound) resembles {v} (Compound) Mitiglinide
Nelfinavir {u} (Compound) resembles {v} (Compound) Indinavir
Nelfinavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Nelfinavir {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
Nelfinavir {u} (Compound) upregulates {v} (Gene) AARS
Nelfinavir {u} (Compound) downregulates {v} (Gene) RPIA
Nelfinavir {u} (Compound) causes {v} (Side Effect) Injury
Nelfinavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ranitidine
Nelfinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Nelfinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin lispro
Nelfinavir (Compound) resembles Mitiglinide (Compound)
Nelfinavir (Compound) resembles Indinavir (Compound)
Nelfinavir (Compound) treats acquired immunodeficiency syndrome (Disease)
Nelfinavir (Compound) binds CYP3A7-CYP3A51P (Gene)
Nelfinavir (Compound) upregulates AARS (Gene)
Nelfinavir (Compound) downregulates RPIA (Gene)
Nelfinavir (Compound) causes Injury (Side Effect)
Nelfinavir may cause a minor interaction that can limit clinical effects when taken with Ranitidine
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro